On November 17, Corcept Therapeutics fell 4.25% in Regular Trading, trading at $69.825 per share, with turnover of $13.8923 million.
The move appears tied to lingering caution after the company reported third-quarter results above expectations but only reiterated full-year revenue guidance, limiting incremental upside for sentiment.
Corcept Therapeutics previously reported Q3 EPS of $1.01, up from $0.16 a year earlier and above consensus estimates of $0.79 to $0.81, while revenue rose to $340.5 million from $207.6 million and also topped forecasts near $336 million. However, the company maintained its full-year revenue outlook at $1.1 billion to $1.2 billion, broadly in line with expectations around $1.15 billion, rather than raising guidance after a strong quarter. Shares had already fallen in after-hours trading following the release, suggesting the earnings beat was largely offset by a lack of stronger forward guidance.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)